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Abstract
Context: Short sleep duration is associated with adverse health outcomes, but the mechanisms involved are unknown. It
has been postulated that short sleep duration may elevate cortisol levels, but studies have had conflicting results. It is
unclear whether these differing findings may be due to methodological issues, such as assessment of sleep duration.
Specifically, objective versus subjective methods of measuring habitual sleep duration may account for the conflicting
results found in epidemiological studies.
Objective: Our goal was to determine whether habitual sleep duration, measured objectively (by actigraphy) and
subjectively (by self-report), was associated with 24-hour urine free cortisol (UFC), a measure of integrated cortisol secretion.
Our secondary goal was to determine whether slow wave sleep (SWS, determined by polysomnography) was associated
with 24-hour UFC.
Design/Setting: Cross sectional study of community dwelling older men.
Patients/Participants: 325 men (mean age=76.6 years, SD=5.5) from the Portland site of the MrOS Sleep Study, who
underwent 24-hour urine collection, polysomnography, actigraphy and sleep questionnaire.
Primary Outcome: 24-hour UFC.
Results: In this study of community dwelling older men, self-reported sleep duration was inversely related to 24-hour UFC
levels. Participants reporting ,5 hours of habitual sleep had an adjusted mean 24-hour UFC of 29.8 ug, compared to
28.0 ug in participants reporting .5t o,8 hours of sleep 25.5 ug in those reporting .8 hours of habitual sleep. However,
sleep duration determined by actigraphy was not associated with 24-hour UFC in either univariable or multivariable
regression models. SWS was not associated with 24-hour UFC.
Conclusion: Objectively measured (i.e., actigraphic) sleep duration is not associated with 24-hour UFC in these community
dwelling older men. This finding, together with prior studies, suggests that elevated levels of integrated cortisol secretion is
not the mechanisms by which short sleep duration leads to adverse health outcomes.
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Introduction
Habitually short sleep duration is endemic in society today [1].
Over the past 50 years, sleep duration in the US has decreased by
1–2 hours per night and more than 50% of adults sleep less than 6
hours per night [1,2]. Recent research has shown that sleep
duration of less than 6 hours, on average, is associated with
adverse health consequences, including impaired glucose toler-
ance, decreased immune function and increased risk of obesity [3–
6]. However, the mechanism by which short sleep duration affects
PLOS ONE | www.plosone.org 1 September 2013 | Volume 8 | Issue 9 | e75205physiological function is still unclear. One possibility is that short
sleep duration is a form of chronic stress. Consequently, the
primary neuroendocrine mediator of stress, the HPA axis, may be
activated, leading to elevated cortisol levels. Indeed, some studies
of sleep restriction in a laboratory setting have found that sleep
deprivation results in increased cortisol levels [7,8]. However,
other laboratory-based studies have reported that cortisol is
unchanged or decreased [9–11]. One large cross-sectional study
has shown that self-reported sleep duration is inversely associated
with salivary cortisol levels [12]. Only one small study (of less than
100 subjects) has tried to answer the question of whether
objectively measured sleep duration is associated with cortisol
levels in a community based population [13]; the authors found no
relation between actigraphic sleep time and morning cortisol
levels. However, this study assessed cortisol level at a single time
point (i.e., upon awakening), which is highly variable. It is
unknown whether integrated cortisol levels (over 24 hours) are
associated with objectively measured sleep duration.
Cortisol can be measured in several ways, and the ideal method
is still unclear [14]. Because cortisol secretion varies widely
throughout the day, single measurements are less informative [14–
16]. Furthermore, because free cortisol (rather than bound) is the
active component, any measurement method should quantify or
estimate this fraction [17]. Lastly, the ideal cortisol measure in
observational studies may be based in part on the research
question, the outcomes being examined and the population under
study [14].
The MrOS Sleep study included over 3000 community dwelling
older men who underwent objective measurements of sleep at
home (actigraphy and polysomnography) and answered a sleep
questionnaire. A subset of the cohort had a 24-hour urine
collection that was assayed for free cortisol. We chose 24-hour
urine free cortisol (UFC) because it is an integrated measure of
cortisol secretion over time, and because it is a measure of free
cortisol levels. Because the MrOS Sleep study is a community
based sample unselected for sleep history, area-under-curve
measures of cortisol excretion may be most accurate. The goal
of the current study was to assess the association between habitual
sleep duration (measured by actigraphy and self-report) and an
integrated measure of cortisol secretion (i.e., 24-hour UFC). Our
secondary goal was to determine the association between pre-
specified sleep architecture (specifically, SWS) and 24-hour UFC.
In this study, we had a unique opportunity to examine both
actigraphic and self-reported sleep data within the same population,
whereas prior studies had only one method for determining sleep
duration (12,13). Other strengths of this study include the
measurement of integrated cortisol secretion (rather than a single
time point) and the use of a community dwelling population of
subjects, which allows for a more realistic assessment of sleep and
cortisol secretion.
Methods
Participants and Study Design
The Osteoporotic Fractures in Men Study (MrOS) is a cohort of
5994 community dwelling men, age 65 and older, who were
enrolled between 2000–2002 at six clinical centers in the United
States [18,19]. The Outcomes of Sleep Disorders in Older Men
Study (MrOS Sleep Study), was an ancillary study that enrolled
3,135 participants from 2003–2005 for a comprehensive sleep
assessment. Participants at one site (Portland, Oregon) were asked
to provide a single 24-hour urine collection; men with inconti-
nence (loss of more than 1 cup a day of urine) were excluded.
Participation was voluntary, with collection on 357 of the 513
participants (70%). 24-hour UFC could be determined for 342
men. Cortisol levels were missing for 15 participants due to: 7 had
missing samples; 4 participants had a UFC values that could not
be measured due to an interfering analyte; 4 participants had
missing information on the total volume of urine collected. Of the
342 with 24-hour UFC data, all had information on self-reported
sleep duration, 320 had actigraphic sleep duration and 334 had
SWS data as measured by polysomnography (PSG). Among these
342 participants, 17 were excluded from the analysis; 2 were
taking prednisone, which affects the measurement of UFC, and 15
had 24-hour UFC data that was pathologically elevated or low
[20–22]. Due to concern about Cushing’s syndrome (in which
cortisol levels are elevated) or adrenal insufficiency (in which
cortisol levels are decreased) confounding the relationship between
sleep and UFC, values that were consistent with these disorders
were not included in these analyses. Thus, the final study sample
consisted of 325 men in the UFC analysis. Compared to the other
2779 men in the MrOS Sleep Study with data for actigraphy or
PSG, this subset of 325 men had similar values for self-reported
and actigraphic sleep duration. The MrOS study protocol and
ancillary studies were approved by the Institutional Review Boards
at each of the participating field sites (University of Alabama at
Birmingham; University of Minnesota; Stanford University;
University of California, San Diego; Oregon Health and Science
University; University of Pittsburgh) and written informed consent
was obtained from each participant prior to enrollment.
Data Collection
24-hour urine collection. For the 24-hour urine collection,
thymol crystal preservative was placed in a 4-liter container,
followed by 70 mL of heavy mineral oil; final weight of the urine
sample was measured. Participants were provided standardized
instructions on performing 24-hour urine collections at home and
a cooler with refrigerant gel packs for cold storage of the urine.
Participants were asked to empty their bladder prior to the start of
the 24-hour urine collection. For the next 24 hours all urine was
collected, including the first morning void, in the urine collection
container. Any urine sample that was lost was recorded. Samples
were returned to the clinic within 48 hours of collection
completion, where the 24-hour urine volume was measured and
samples were stored at 220uC. An effort was made to have the 24-
hour urine collection coincide with the actigraph recording. Urine
collection and actigraphy coincided in most men (n=280, 87%).
Of those who did not coincide, 24-hour urine collection for 8 men
was within 1 week of the actigraphy recording and was .2 weeks
from the actigraphy recording for 16 men. Twenty-three men with
24-hour urine collection did not have usable actigraph data. In
addition, 94% of men (n=308) collected their 24-hour urine
within 1 week of the in-home PSG recording.
24-hour Urine Free Cortisol (UFC) assay. UFC was
measured at Esoterix Laboratory (Calabassas Hills, CA) using
high performance liquid chromatography tandem mass spectrom-
etry. Urine creatinine was measured (using a Jaffe Reaction) to
verify the accuracy of the24 hour urine collection. Each sample
was measured once for UFC and creatinine. Seventeen samples
were randomly chosen to be run in duplicate. The intra-assay
coefficient of variation for UFC was 5.7%.
Assessment of habitual sleep duration. Participants were
asked about habitual sleep duration with the question ‘‘On most
nights, how many hours do you sleep each night?’’, with data
collected rounded up to the hour. Actigraphic sleep duration was
measured using the SleepWatch-O (Ambulatory Monitoring, Inc.,
Ardsley, NY) worn continuously for a minimum of 5 nights (mean
6 SD, 5.260.9 nights). Participants were instructed to wear the
Sleep Duration and 24-hour UFC
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bathing or during water sports. The actigraph detects movement
via a piezoelectric beam. Actigraphy has been shown to provide a
reliable estimate of sleep-wake patterns [23]. Data were collected
in 3 modes but are reported here based on digital integration
mode (i.e., proportional integration mode) [24]. ActionW-2
software (Ambulatory Monitoring, Inc., Ardsley, NY) was used
to analyze the actigraphy data. Details of the actigraphy scoring
algorithms used have been published elsewhere [25,26]. Partici-
pants completed sleep diaries for the time period they wore the
actigraph. The diaries included time into and time out of bed and
times the actigraph was removed. This information was used in
editing the actigraphy data files. Inter-scorer reliability for editing
the actigraphy data files has been excellent in our group (intra-
class coefficient=0.95) and actigraphic sleep duration has been
shown to have good concordance with sleep duration from PSG
[27].
Variables estimated from actigraphy used in this analysis
included: 1) sleep duration: the hours per night spent sleeping
while in bed after lights off; 2) sleep efficiency (SE), a measure of
sleep fragmentation: the percentage of time in bed after lights off
spent sleeping; 3) wake after sleep onset (WASO), a measure of
sleep fragmentation: minutes of wake after sleep onset during the
in bed interval, with sleep onset defined as the point when the
participant achieved a 20-minute continuous block of sleep after
lights off. All variables from actigraphy reflect data averaged over
all nights they wore the device.
PSG. In-home sleep studies were completed using unattended,
portable PSG (Safiro, Compumedics, Inc.H). The recording
montage was as follows: C3/A2 and C4/A1 electroencephalograms
(EEG), bilateral electro-oculograms and a bipolar submental
electromyogram to determine sleep status; thoracic and abdominal
respiratory inductance plethysmography to determine respiratory
effort; airflow (by nasal-oral thermocouple and nasal pressure
cannula); finger pulse oximetry; electrocardiogram; body position
(mercury switch sensor); and bilateral tibialis leg movements
(piezoelectric sensors). Trained, certified staff members performed
home visits to set-up the units, similar to the protocol used in the
Sleep Heart Health Study [28]. After data were downloaded, the
data were transferred to the Central Sleep Reading Center
(Cleveland, OH) to be scored by certified research polysomnol-
ogists. The overall failure rate for the home sleep studies was less
than 4% and more than 70% of the studies were graded as being
of excellent or outstanding quality [28]. Sleep stages were scored
using standard criteria [29]. Data from EEG leads C3 and C4 were
used to score sleep stages 3 and 4, slow wave sleep, presented as
the percent of total sleep time spent in SWS. The inter-scorer
reliability of SWS was 0.96, with even higher levels of intra-scorer
reliability [30].
Other covariates. All participants completed questionnaires
at the time of the clinic visit, which included items about
demographics, medical history, physical activity, smoking and
alcohol use. Physical activity was assessed using the Physical
Activity Scale for the Elderly (PASE) [31]. Weight and height were
measured using a standard balance beam or digital scale, and
height using a wall-mounted Harpenden stadiometer (Holtain,
UK), respectively, to calculate body mass index (BMI). Comor-
bidities included any reported history of current or prior diabetes
mellitus or cardiovascular disease. Insomnia was self-reported as
having trouble getting to sleep or waking at night 3 times or more
per week. Depression was defined as a score of .=6 on the
Geriatric Depression Scale [32]. The measure of sleep disordered
breathing (SDB) used in this analysis was the apnea-hypopnea
index (AHI). Apnea was defined as complete or near complete
cessation of airflow for .10 seconds, and hypopneas were scored if
clear reductions in breathing amplitude (at least 30% below
baseline breathing) occurred, and lasted .10 seconds [33]. Only
apneas and hypopneas that were each associated with 3% or
greater desaturation were included in these analyses. AHI was
calculated as the total number of apneas and hypopneas per hour
of sleep. The inter-scorer reliability for AHI was high (ICC=0.99).
Statistical Analysis
The outcome variable in the current analysis was UFC.
Predictor variables consisted of: (a) self-reported sleep duration;
(b) actigraphic sleep duration; and (c) SWS from home PSG. The
predictor variables were expressed categorically to account for any
non-linear associations with the outcomes (sleep duration as #5
hours, .5t o,8 hours, .8 hours; SWS as quartiles). The cut-offs
for categories of habitual sleep duration were chosen after
assessing other possible categorizations. Baseline characteristics
were summarized as means and standard deviations (SD) for
continuous covariates, and counts and percentages for categorical
data. These characteristics were compared across categories of the
predictors, using ANOVA for continuous variables with normal
distributions, Kruskal-Wallis tests for continuous variables with
skewed distributions, and chi-square tests for categorical data.
Linear regression was used to assess the relationship of the
predictor with the continuous outcome of 24-hour UFC. Tests for
linear trend were performed by including the predictor variable as
an ordinal variable in the models. Results were presented as
adjusted means and 95% confidence intervals across quartiles or
categories, calculated using the least-squares means procedure and
a P-value test for a linear trend across categories. All models were
first adjusted for age and then adjusted for other covariates.
Potential confounding variables, identified a priori included race,
BMI, physical activity, AHI, alcohol use, smoking status, history of
diabetes, history of CVD, presence of depression, and sleep
efficiency. Any covariate associated with the outcome or one or
more predictors at a p,0.10 in univariate analyses was included in
the multivariable model. These covariates were entered into
sequential models, thereby assessing their incremental effects. The
minimally adjusted model was adjusted for age, race and AHI.
The multivariable adjusted model included age, race, AHI, as well
as BMI, history of CVD, number of depressive symptoms, and
physical activity. The models with actigraphic sleep duration and
SWS as predictor variables were further adjusted for sleep
efficiency.
The interaction of depression and insomnia and these sleep
predictors was examined. To enable comparability to other studies
of younger populations, the interactions of the predictors with age
(,75 vs $75 years old) were explored. The interaction of the sleep
predictors and history of CVD was also examined, due to the
strong association of CVD with circadian rhythms (and, poten-
tially, with cortisol) [34]. Stratifications by these parameters were
performed where appropriate (when interaction p,0.10 in models
adjusted for age, the predictor, stratification term and the
interaction of the predictor and the stratification term).
Secondary analyses were conducted in the models with the
predictors as a continuous variable; because the results did not
significantly differ, only data with the predictor expressed as a
categorical variable are presented. Sleep duration by PSG was also
assessed as a predictor variable; because the results did not differ
from actigraphic sleep duration, we report only the latter.
Sensitivity analyses were performed using categorically defined
depression rather than the number of depressive symptoms in the
multivariable models. Sensitivity analysis was also performed in
the 280 men who had actigraphy coinciding with the urine
Sleep Duration and 24-hour UFC
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examined by calculating the variance inflation factor (VIF) for
each variable. The maximum VIF was 1.17, indicating a low
degree of multicollinearity. Regression diagnostics were performed
on the data. All analyses were performed using SAS statistical
software (version 9.2, SAS Institute, Inc., Cary, NC).
Results
Table 1 summarizes the baseline characteristics of the
participants included in this analysis. These subjects (n=325)
were similar to the larger MrOS Sleep Study cohort (n=3104)
with respect to age (77 vs. 76, p=0.5), race/ethnicity (91% vs.
90% Caucasian, p=0.14) and co-morbidities such as history of
cardiovascular disease (31% vs. 33%, p=0.3). The mean 24-hour
UFC was 27.2 mg (SD 13.2), and average actigraphic sleep
duration was 6.4 hours (SD 1.3).
The average of self-reported sleep duration was higher than
average sleep estimated by actigraphy (7.061.2 hours vs. 6.461.3
hours, p,0.001, respectively). Approximately 9% of men slept less
than 5 hours per night (self-report 8.9%, actigraphic 10.5%). The
proportion of men with 8 or more hours of sleep per night differed
between self-report and actigraphy (self-reported 34.2%, acti-
graphic 7.2%). There was only 54% agreement between the 2
measures across the categories, and the correlation of the linear
representations was modest (r=0.31). On average, those in the
lower category of actigraphic sleep duration had higher levels of
BMI and AHI and lower levels of sleep efficiency (p,0.05). Those
in the lower category of self-reported sleep duration were less likely
to be Caucasian and were more likely to report insomnia (p,0.05).
On average, the total duration of SWS was 46 minutes and
accounted for 12% of sleep duration. SWS was significantly
associated only with race. UFC was associated to physical activity
and history of CVD.
In the age-adjusted analysis (Table 2), there was an inverse
association between self-reported sleep duration and 24-hour UFC
(p=0.08). In participants who reported 5 hours or less of habitual
sleep, the adjusted mean 24-hour UFC was 29.2 mg, compared to
27.9 mg in those who reported .5t o,8 hours of sleep and
25.4 mg in those reporting 8 hours or more of sleep. In
multivariable models adjusting for potential confounders, an
inverse relationship was observed between self-reported sleep
duration and 24-hour UFC (p=0.058). Participants who reported
5 hours or less of habitual sleep had an adjusted mean 24-hour
UFC of 29.8 mg (95% CI: 25.0, 34.7), compared to 28.0 mg (95%
CI: 26.1, 29.8) in participants reporting .5t o,8 hours of sleep
and 25.5 mg (95% CI: 23.1, 27.9) in those reporting 8 hours or
more of sleep. Sensitivity models replacing the number of
depressive symptoms with the presence of depression (as a
covariate) in the multivariable models showed similar adjusted
means and a slight improvement in statistical significance (P-
trend=0.047). Sensitivity analysis was also performed in the 280
men who had urine collection coinciding with actigraphy; the
results in this subset were similar to that of the larger group.
Restricting the analyses to participants without depression or a
history of CVD showed a significant association between 24-hour
UFC and self-reported sleep duration (P-trend=0.03 for both
models, Figure 1). Among those 306 men classified as not
depressed (GDS,6) there is a linear trend across category of
self-reported sleep duration, with those reporting ,5 hours having
an adjusted mean 24-hour UFC of 30.0 mg, and those with .8
hours of sleep duration having an adjusted mean value of 25.2 mg
(P-trend=0.03 and P-interaction=0.09). While the interaction of
history of CVD and self-reported sleep duration was not significant
(P-interaction=0.43), among those 225 men without a history of
CVD there was a significant association of self-reported sleep
duration and 24-hr UFC (P-trend=0.03, Figure 1). There were no
significant interactions between self-reported sleep duration and
insomnia or age.
No significant associations were noted between 24-hour UFC
and actigraphic sleep duration despite incremental adjustments for
age, race, AHI, BMI, history of CVD, physical activity and
number of depression symptoms (Table 2). Results were similar
after further adjusting the multivariable models by sleep efficiency.
There were no significant interactions of actigraphic sleep
duration and age, depression, history of CVD or insomnia.
Results were similar when replacing actigraphic sleep duration by
PSG-measured sleep duration.
Table 1. Baseline Characteristics.
Characteristic (N=325)
Age, mean 6 SD, y 76.665.5
Non-Caucasian race, n (%) 29 (8.9)
Body mass index, kg/m
2, mean 6 SD 26.863.6
PASE score, mean 6 SD 148.0669.7
Apnea-hypopnea Index, mean 6 SD 14.3614.0
Insomnia, n (%) 193 (59.4)
Alcohol intake in past 12 months (drinks/week), n (%)
0–2 169 (52.3)
3–13 133 (41.2)
$14 21 (6.5)
Smoking, n (%)
Never 135 (41.5)
Past 183 (56.3)
Current 7 (2.2)
History of diabetes mellitus, n (%) 42 (12.9)
History of CVD*, n (%) 99 (30.6)
Geriatric Depression Score (0–15), mean 6 SD 1.762.1
GDS$6 (depressed), n (%) 19 (5.9)
Sleep Variables
Actigraphic sleep duration, hrs, mean 6 SD 6.461.3
Actigraphic sleep categories, n (%)
#5 hrs 32 (10.5)
.5t o,8 hrs 250 (82.2)
$8 hrs 22 (7.2)
Duration of slow wave sleep, min, mean 6 SD 45.9632.5
% of sleep time spent in slow wave sleep, mean 6 SD 12.969.1
Self-reported sleep duration, mean 6 SD 7.061.2
Self-reported sleep categories, n (%)
#5 hrs 29 (8.9)
.5t o,8 hrs 185 (56.9)
$8 hrs 111 (34.2)
Sleep efficiency, %, mean 6 SD 78.9611.9
WASO, min, mean 6 SD 73.9639.8
24-hours urine free cortisol, mg, mean 6 SD 27.2613.2
*CVD includes history of myocardial infarction, angina, congestive heart failure,
bypass surgery, angioplasty, or pacemaker placement.
doi:10.1371/journal.pone.0075205.t001
Sleep Duration and 24-hour UFC
PLOS ONE | www.plosone.org 4 September 2013 | Volume 8 | Issue 9 | e75205No significant association between SWS and 24-hour UFC was
observed in any of models (Table 2). There were no significant
interactions of SWS and age, depression, history of CVD or
insomnia.
Discussion
The primary finding of the current study is the lack of
association between objectively measured (i.e. actigraphic) sleep
duration and integrated cortisol levels in either unadjusted or
adjusted analyses. Interestingly, we found an inverse association
Figure 1. Association of self-reported sleep duration and 24-hour urine free cortisol among those without depression and those
without a history of CVD. 24-hour urine free cortisol results are adjusted means (95% confidence intervals). Results for the not depressed sub-
group adjusted for age, race, apnea-hypopnea index, BMI, history of CVD and physical activity. Results from those without a history of CVD adjusted
for age, race, apnea-hypopnea index, BMI, physical activity, and number of depressive symptoms.
doi:10.1371/journal.pone.0075205.g001
Table 2. Associations of Sleep Characteristics and 24-hour Urine Free Cortisol, mg, Adjusted Means (95% Confidence Intervals).
Age Minimally Multivariable
Multivariable
+ Sleep Fragmentation
Sleep Characteristic Adjusted Adjusted
a Adjusted
b Adjusted
c
Self-Reported Sleep Duration
#5 hrs (n=29) 29.2 (24.4, 34.0) 29.0 (24.2, 33.9) 29.8 (25.0, 34.7) –
.5t o,8 hrs (n=185) 27.9 (26.0, 29.8) 28.0 (26.1, 29.9) 28.0 (26.1, 29.9) –
$8 hrs (n=111) 25.4 (23.0, 27.8) 25.5 (23.1, 28.0) 25.5 (23.1, 27.9) –
P-trend 0.076 0.101 0.058 –
Actigraphic Sleep Duration
#5 hrs (n=32) 24.9 (20.2, 29.5) 25.2 (20.4, 29.9) 25.1 (20.4, 29.8) 26.5 (20.5, 32.5)
.5t o,8 hrs (n=250) 27.6 (25.9, 29.2) 27.7 (26.0, 29.4) 27.9 (26.2, 29.5) 27.7 (26.0, 29.4)
$8 hrs (n=22) 26.0 (20.4, 31.5) 25.7 (20.0, 31.3) 24.7 (19.2, 30.3) 24.1 (18.3, 29.9)
P-trend 0.63 0.76 0.92 0.55
% of Sleep time spent in SWS
Q1:,5.06% (n=79) 28.7 (25.8, 31.6) 28.6 (25.6, 31.6) 28.7 (25.8, 31.6) 28.5 (25.4, 31.5)
Q2:5.06 to ,11.90% (n=80) 24.8 (21.9, 27.7) 24.8 (21.9, 27.7) 24.7 (21.9, 27.6) 24.7 (21.7, 27.7)
Q3:11.90 to ,18.90% (n=79) 29.2 (26.3, 32.1) 29.3 (26.3, 32.2) 29.4 (26.5, 32.2) 29.8 (26.8, 32.8)
Q4: $18.90% (n=80) 26.1(23.2, 28.9) 26.2 (23.3, 29.1) 26.2 (23.3, 29.1) 26.2 (23.2, 29.2)
P-trend 0.60 0.70 0.70 0.85
aAdjusted for age, race, apnea-hypopnea index.
bAdjusted for age, race, apnea-hypopnea index, BMI, history of CVD, physical activity, number of depression symptoms.
cAdjusted for age, race, apnea-hypopnea index, BMI, history of CVD, physical activity, number of depressive symptoms, sleep efficiency.
doi:10.1371/journal.pone.0075205.t002
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levels even after adjusting for several confounding variables. The
association was particularly strong in men without prevalent CVD
and depression.
An emerging body of evidence indicates that short sleep
duration may cause insulin resistance, glucose intolerance, and
obesity [2–4]. However, the mechanisms by which this may occur
remain unclear. Possible candidates include increase in cortico-
trophin activity, altered levels of circulating adipocytokines,
decreased energy expenditure, and changes in activity levels.
The majority of studies assessing cortisol levels have been
performed in healthy volunteers under tightly controlled labora-
tory conditions with severe curtailment of total sleep time. While
some studies have shown that cortisol levels are elevated [7,8],
others have shown that cortisol is unchanged or even decreased
[9–11] as sleep duration in decreased. There are only two studies
of community-based individuals in which the association between
cortisol and sleep duration have been determined. In the
Whitehall study of over 2700 men and women, Kumari et al
found that self-reported short sleep duration was associated with a
flatter diurnal slope of cortisol secretion and increased cortisol
awakening response [12]. The Whitehall study used multiple
salivary cortisol measurements taken over 1 day to provide an
integrated measure of cortisol secretion, but sleep duration was
based on self-report. A small (n=90), community-based study
found no association between sleep duration and morning salivary
cortisol levels [13]. Although sleep duration was measured by
actigraphy, the investigators assessed cortisol levels at a single time
point. Due to the significant daily fluctuation of cortisol, single
measurements are often unreliable [14].
The discrepancy we found between objective and subjective
sleep in the analyses presented herein suggests a way to reconcile
the findings of the other 2 community based studies. In this current
analysis, both objective and subjective assessments of sleep
duration are available within the same population. The correlation
between self-reported and actigraphic sleep duration was modest
overall (r=0.31), and there was only 54% agreement between the
2 measures across categories. We found no association between
objectively measured sleep duration and integrated cortisol levels,
but did observe an inverse association between self-reported sleep
duration and integrated cortisol levels. One possible explanation
for this discrepancy is that self-reported sleep is a surrogate for
other issues. For example, it is possible that those with more
anxiety or ‘‘hyperarousal’’ report less subjective sleep. More
generally, self-reported sleep time may be a marker for other
social, psychological or physical issues. For example, self-reported
sleep may be reflective of poor sleep quality due to depression,
insomnia, or other factors. Lastly, self-reported sleep may be
indicative of sleep duration over a longer period of time (i.e., weeks
to months), whereas actigraphy measured sleep duration over
5 days (in this cohort).
Studies that have assessed the association between objective and
subjective sleep duration have had similar findings regarding the
discordance between objective and subjective sleep duration
[35,36].
Lauderdale et al found that subjective sleep measurement was
greater than objective sleep duration due, most likely, to
inaccurate reporting of how much an individual sleeps on a single
night [35]. In a small study (n,100) of post-menopausal women,
Regestein et al found a similar discrepancy between self-reported
and actigraphic sleep times [36]. Interestingly, Regestein et al
found that high hyperarousal scores (on a Hyperarousal Scale)
were associated with underestimations of objective sleep;
participants in the lowest hyperarousal score quartile overesti-
mated their objective sleep. The investigators also found that
increased psychological and somatic symptoms were associated
with self-reported low sleep quality.
The current study has several important limitations that warrant
consideration. First, the MrOS cohort was older in age, male, and
predominantly Caucasian, thereby limiting the generalizability of
our findings. Second, the 24-hour urine collection was performed
at home, not in a laboratory, so the accuracy of the collection
cannot be absolutely determined. The strengths of this study
include the use of both actigraphic and self-reported sleep data
within the same population, allowing for the comparison of the
two. Furthermore, cortisol was measured using an integrated
measure of secretion (24-hour UFC), rather than a single time
point, which is highly unreliable due to its daily variability. Finally,
the fact that participants were in their usual environment (rather
than a laboratory setting) allows for a more realistic assessment of
their sleep and possibly of their cortisol secretion. In conclusion,
we found that objectively measured sleep duration was not
associated with integrated cortisol levels in this cohort of
community dwelling men. This finding, together with prior
studies, suggest that elevated levels of integrated cortisol secretion
are not the mechanism by which short sleep duration leads to
adverse health outcomes. Further studies will need to be done to
confirm these findings in other groups, including those that are
young and female.
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